Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.

doi:10.1080/10428194.2020.1864354

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.

Leukemia & lymphoma - 1 Jun 2021

Middeke Jan M, Teipel Raphael, Röllig Christoph, Stasik Sebastian, Zebisch Armin, Sill Heinz, Kramer Michael, Scholl Sebastian, Hochhaus Andreas, Jost Edgar, Brümmendorf Tim H, Naumann Ralph, Steffen Björn, Serve Hubert, Altmann Heidi, Kunzmann Volker, Einsele Hermann, Parmentier Stefani, Schaich Markus, Burchert Andreas, Neubauer Andreas, Schliemann Christoph, Berdel Wolfgang E, Sockel Katja, Stölzel Friedrich, Platzbecker Uwe, Ehninger Gerhard, Bornhäuser Martin, Schetelig Johannes, Thiede Christian

Abstract excerpt

We performed a registry-based analysis of 311 AML patients treated with decitabine in a standard of care setting to assess response and survival data with a distinct focus on the impact of the TP53 mutation status. Median age was 73 years. 172 patients received decitabine first-line and 139 in r/r disease. The ORR (whole cohort) was 30% with a median overall survival of 4.7 months. First-line patients achieved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to DNA Mutational Analysis

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Registries

Share to Treatment Outcome

Share to Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 33399480
DOI: 10.1080/10428194.2020.1864354

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.PMID 33399480Read ↗

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.Semantic proximity Read ↗

Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation.Semantic proximity Read ↗

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.Semantic proximity Read ↗

Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome.Semantic proximity Read ↗

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialSemantic proximity Read ↗

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experienceSemantic proximity Read ↗

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).Semantic proximity Read ↗

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine.Semantic proximity Read ↗

Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy.Semantic proximity Read ↗

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical DevelopmentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.